BALAXI

Balaxi Pharmaceuticals Share Price

 

 

Start SIP in BALAXI

Start SIP
Balaxi Pharmaceuticals live price: ₹21.45. It opened at ₹22 vs previous close ₹21; intraday high/low: ₹22/₹21. The 50 & 200 DMA stand at ₹21.17/₹36.02.

Balaxi Pharmaceuticals Performance

  • Today's Low
  • ₹21
  • Today's High
  • ₹22
  • 52 Week Low
  • ₹15
  • 52 Week High
  • ₹74
  • Open Price₹22
  • Previous Close₹21
  • Volume78,260
  • 50 DMA₹21.17
  • 100 DMA₹26.26
  • 200 DMA₹36.02

Investment Returns

  • Over 1 Month + 18.12%
  • Over 3 Month -22.11%
  • Over 6 Month -52.22%
  • Over 1 Year -67.99%

Smart Investing Starts Here Start SIP with Balaxi Pharmaceuticals for Steady Growth!

Invest Now

Balaxi Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 12.5
  • PEG Ratio
  • -0.2
  • Market Cap Cr
  • 118
  • P/B Ratio
  • 0.5
  • Average True Range
  • 1.63
  • EPS
  • 1.71
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.09
  • RSI
  • 58.7
  • MFI
  • 39.04

Balaxi Pharmaceuticals Financials

Balaxi Pharmaceuticals Technicals

EMA & SMA

Current Price
₹21.45
+ 0.33 (1.56%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹18.64
  • 50 Day
  • ₹21.17
  • 100 Day
  • ₹26.26
  • 200 Day
  • ₹36.02

Resistance and Support

20.37 Pivot Speed
  • R3 26.69
  • R2 24.33
  • R1 22.73
  • S1 18.77
  • S2 16.41
  • S3 14.81

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Balaxi Pharmaceuticals has an operating revenue of Rs. 275.73 Cr. on a trailing 12-month basis. An annual revenue growth of 21% is outstanding, Pre-tax margin of 10% is healthy, ROE of 10% is good. The company has a reasonable debt to equity of 9%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 13 which is a POOR score indicating inconsistency in earnings, a RS Rating of 6 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 28 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Balaxi Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-28 Quarterly Results & Others To consider other business matters. split from Rs. 10/- to Rs. 2/-.
2025-11-11 Quarterly Results & Others
2025-08-05 Quarterly Results & Others To consider other business matters. split from Rs. 10/- to Rs. 2/-.
2025-05-30 Audited Results & Others To consider other business matters. split from Rs. 10/- to Rs. 2/-.
2025-02-10 Quarterly Results & Others To consider other business matters. split from Rs. 10/- to Rs. 2/-.
Date Purpose Remarks
2024-05-30 Split Rs.0.00 split from Rs. 10/- to Rs. 2/-.

Balaxi Pharmaceuticals F&O

Balaxi Pharmaceuticals Shareholding Pattern

65.99%
1.74%
0.02%
22.39%
9.86%

Balaxi Pharmaceuticals FAQs

Balaxi Pharmaceuticals share price is ₹21 As on 06 April, 2026 | 12:28

The Market Cap of Balaxi Pharmaceuticals is ₹118.4 Cr As on 06 April, 2026 | 12:28

The P/E ratio of Balaxi Pharmaceuticals is 12.5 As on 06 April, 2026 | 12:28

The PB ratio of Balaxi Pharmaceuticals is 0.5 As on 06 April, 2026 | 12:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23